QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VIR

QT62Vir Biotechnology, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
9.16
-0.14-1.51%
OverviewShort InterestFilings
VIRQT62Vir Biotechnology, Inc.·NASDAQ
OverviewShort InterestFilings
9.16-1.51%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-4.00
Insider Own49.32%
Shs Outstand168.65M
Perf Week7.51%
Market Cap1.57BForward P/E-EPS next Y-2.33Insider Trans-0.13%Shs Float-Perf Month7.39%
Enterprise Value1.39BPEG-EPS next Q0.33Inst Own-Short Float-Perf Quarter-2.35%
Income-506770511.00P/S23.95EPS this Y51.66%Inst Trans-Short Ratio-Perf Half Y41.36%
Sales65.49MP/B1.69EPS next Y-20.57%ROA-43.17%Short Interest-Perf YTD51.91%
Book/sh4.82P/C-EPS next 5Y-ROE-53.31%52W High11.66 -21.44%Perf Year79.61%
Cash/sh2.80P/FCF-EPS past 3/5Y-ROIC-48.04%52W Low4.16 120.19%Perf 3Y-
Dividend Est.-EV/EBITDA-3.17Sales past 3/5Y-65.05% 0.59%Gross Margin275.25%Volatility3.54% 3.39%Perf 5Y-
Dividend TTM-EV/Sales21.19EPS Y/Y TTM18.28%Oper. Margin-704.87%ATR (14)0.48Perf 10Y-
Dividend Ex-Date-Quick Ratio7.11Sales Y/Y TTM-75.68%Profit Margin-675.96%RSI (14)52.83Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.11EPS Q/Q3.41%SMA202.83%Beta1.98Target Price21.71
Payout0.00%Debt/Eq0.12Sales Q/Q-100.00%SMA50-3.35%Rel Volume4.82Prev Close9.30
Employees408LT Debt/Eq0.23EarningsAug 05SMA20022.87%Avg Volume1.83MPrice9.16
IPO DateOct 11, 2019Option/ShortYes / YesEPS/Sales Surpr.-8400.00% -100.00%Net Debt/EBITDA0.41Volume8,795,015Change-1.51%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-11-26ReiteratedMorgan StanleyOverweight$23 → $27
May-08-26ReiteratedMorgan StanleyOverweight$24 → $23
Mar-04-26ReiteratedH.C. Wainwright$15 → $20
Feb-26-26ReiteratedLeerink PartnersOutperform$20
Feb-24-26ReiteratedEvercore ISI$12 → $18
Feb-24-26ReiteratedRaymond James$12 → $19
Feb-24-26ReiteratedMorgan StanleyOverweight$20 → $24
Feb-24-26ReiteratedNeedhamBuy$35 → $18
Feb-17-26ReiteratedBarclaysOverweight$24 → $26
Feb-04-26ReiteratedBarclaysOverweight$31 → $24
Latest News
Jun-11-26
Jun-11-2608:30AM
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27Benzinga
08:30AM
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue186974
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A50012479
Gross Profit-48057-404
Selling, General and Administrative Excl. Other0920
Research and Development518433506
Other Operating Expense-3920-323
Operating Income-606-468-587
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-28-30-64
Net Income Before Taxes-551-438-523
Income Taxes00-1
Consolidated Net Income-551-438-522
Net Income From Continuing Operations-551-438-522
Net Income-551-438-522
EPS (Recurring)-4.00-3.16-3.83
EPS (Basic, Before Extraordinaries)-4.00-3.16-3.83
EPS (Diluted)-4.00-3.16-3.83
EBITDA-568-426-509
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio70.2312.15—
Gross Margin-2,666.6782.61-545.95
Operating Margin-3,366.67-678.26-793.24
Net Margin-3,061.11-634.78-705.41
Shares Outstanding138139136
Market Capitalization1,264838—
Operating Lease Expense
———
Insider Trading Volume
$10.58$9.93$9.29$8.64$7.99● Close Price0.00M3.18M6.35M9.53M12.71MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Napolitano JanetDirectorJun 01 '26Sale9.453,20030,24021,216Jun 02 12:00 AM
Sabatini BrentSVP, Chief Accounting OfficerJun 01 '26Sale9.453793,58261,902Jun 02 12:00 AM
SATO VICKI LDirectorMay 01 '26Sale10.0522,000221,0251,078,391May 04 12:00 AM
De Backer MariannePresident and CEOApr 06 '26Sale9.1672,559664,350948,145Apr 07 12:00 AM
SATO VICKI LDirectorApr 01 '26Sale9.0722,000199,6171,100,391Apr 02 12:00 AM
Sabatini BrentSVP, Chief Accounting OfficerMar 23 '26Sale9.127,71170,32461,902Mar 24 12:00 AM
SATO VICKI LDirectorMar 02 '26Sale9.5122,000209,1811,122,391Mar 03 12:00 AM
Eisner MarkEVP and Chief Medical OfficerFeb 25 '26Sale9.821,88918,550154,024Feb 26 12:00 AM
de Verneuil VaninaEVP, General Counsel, Corp SecFeb 25 '26Sale9.8213,700134,534112,982Feb 26 12:00 AM
Eisner MarkEVP and Chief Medical OfficerFeb 24 '26Sale9.531,61615,405155,913Feb 26 12:00 AM
SATO VICKI LDirectorFeb 24 '26Option Exercise1.4984,754125,8601,186,768Feb 26 12:00 AM
SATO VICKI LDirectorFeb 24 '26Sale9.7542,377413,3661,144,391Feb 26 12:00 AM
Sabatini BrentSVP, Chief Accounting OfficerFeb 24 '26Sale9.531,43013,63269,613Feb 26 12:00 AM
O'Byrne JasonEVP & Chief Financial OfficerFeb 24 '26Sale9.531,63415,576162,615Feb 26 12:00 AM
de Verneuil VaninaEVP, General Counsel, Corp SecFeb 24 '26Sale9.533,11729,713126,682Feb 26 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR